The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Bortezomib Accord bortezomib Generic | Accord Healthcare S.L.U. | Multiple Myeloma | 🇪🇺 EU 2015-07-20 | Order → |
| Nivolumab BMS nivolumab | Bristol-Myers Squibb Pharma EEIG | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2015-07-20 | Order → |
| Keytruda pembrolizumab | Merck Sharp & Dohme B.V. | Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urolog | 🇪🇺 EU 2015-07-17 | Order → |
| Pregabalin Zentiva pregabalin Generic | Zentiva k.s. | Anxiety Disorders; Epilepsy | 🇪🇺 EU 2015-07-17 | Order → |
| Repatha evolocumab | Amgen Europe B.V. | Dyslipidemias; Hypercholesterolemia | 🇪🇺 EU 2015-07-17 | Order → |
| Evotaz atazanavir;cobicistat | Bristol-Myers Squibb Pharma EEIG | HIV Infections | 🇪🇺 EU 2015-07-13 | Order → |
| Hetlioz tasimelteon | Vanda Pharmaceuticals Netherlands B.V. | Sleep Disorders, Circadian Rhythm | 🇪🇺 EU 2015-07-03 | Order → |
| Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen) aripiprazole Generic | Mylan Pharmaceuticals Limited | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2015-06-30 | Order → |
| Aripiprazole Zentiva aripiprazole Generic | Zentiva k.s. | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2015-06-25 | Order → |
| Pregabalin Mylan Pharma pregabalin Generic | Mylan S.A.S. | Anxiety Disorders; Neuralgia; Epilepsy | 🇪🇺 EU 2015-06-25 | Order → |
| Pregabalin Viatris (previously Pregabalin Mylan) pregabalin Generic | Viatris Limited | Anxiety Disorders; Epilepsy | 🇪🇺 EU 2015-06-24 | Order → |
| Duloxetine Viatris (previously Duloxetine Mylan) duloxetine Generic | Viatris Limited | Neuralgia; Diabetic Neuropathies; Depressive Disorder, Major; Anxiety Disorders | 🇪🇺 EU 2015-06-19 | Order → |
| Lixiana edoxaban | Daiichi Sankyo Europe GmbH | Stroke; Venous Thromboembolism | 🇪🇺 EU 2015-06-19 | Order → |
| Opdivo nivolumab | Bristol-Myers Squibb Pharma EEIG | Melanoma; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Urolog | 🇪🇺 EU 2015-06-19 | Order → |
| Pregabalin Sandoz pregabalin Generic | Sandoz GmbH | Anxiety Disorders; Neuralgia; Epilepsy | 🇪🇺 EU 2015-06-19 | Order → |
| Pregabalin Sandoz GmbH pregabalin Generic | Sandoz GmbH | Anxiety Disorders; Epilepsy | 🇪🇺 EU 2015-06-19 | Order → |
| Lumark lutetium (177Lu) chloride | I.D.B. Radiopharmacy B.V. | Radionuclide Imaging | 🇪🇺 EU 2015-06-18 | Order → |
| Gardasil 9 human papillomavirus 9-valent vaccine (recombinant, adsorbed) | Merck Sharp & Dohme B.V. | Condylomata Acuminata; Papillomavirus Infections; Immunization; Uterine Cervical Dysplasia | 🇪🇺 EU 2015-06-10 | Order → |
| Lenvima lenvatinib Accelerated assessment | Eisai GmbH | Thyroid Neoplasms | 🇪🇺 EU 2015-05-28 | Order → |
| Akynzeo netupitant;palonosetron | Helsinn Birex Pharmaceuticals Ltd | Vomiting; Neoplasms; Nausea; Cancer | 🇪🇺 EU 2015-05-27 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.